`FORM 10-QSB/A

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                      For Quarter Ended September 30, 2001

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For the transition period from to

                         Commission file number: 0-27847

                      JACOBSON RESONANCE ENTERPRISES, INC.
         ---------------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

             Nevada                                      65-0684400
    ------------------------------------------------------------------------
    State or other jurisdiction of                     I.R.S. Employer
    incorporation or organization                      Identification No.

             8200 Jog Road, Suite 100, Boynton Beach, Florida 33437
     -----------------------------------------------------------------------
                     (Address of Principal Executive Office)

                                 (561) 752-4141
                              --------------------
               (Registrant's telephone number including area code)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
     Yes X No ___

The number of shares of registrant's Common Stock, $.001 par value, outstanding
as of September 30, 2001 was 57,369,239 shares.







                      JACOBSON RESONANCE ENTERPRISES, INC.

INDEX

                                                                            Page

PART I  - FINANCIAL INFORMATION:

     ITEM 1.  FINANCIAL STATEMENTS

              Balance Sheet _ September 30, 2001 and December 31, 2000         1

              Statement of Operations for the Three and Nine Months
              Ended September 30, 2001 and 2000 and for the Period from
              Inception to September 30, 2001                                  2

              Statement of Changes in Stockholders' Equity from
              Inception to September 30, 2001                                  3

              Statement of Cash Flows for the Nine Months Ended
              September 30, 2001 and 2000 and for the Period from
              Inception to September 30, 2001                                4-5

              Notes to Financial Statements                                  6-8

     ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS

PART II  _ OTHER INFORMATION:

     ITEM 1.  LEGAL PROCEEDINGS                                                9

     ITEM 2.  CHANGES IN SECURITIES                                            9

     ITEM 3.  DEFAULTS UPON SENIOR SECURITIES                                  9

     ITEM 4.  SUBMISSIONS OF MATTERS TO A VOTE OF
                      SECURITY HOLDERS                                         9

     ITEM 5.  OTHER EVENTS                                                     9

     ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K                                 9

SIGNATURES                                                                    10

                           FORWARD LOOKING STATEMENTS

     When used in this report, the words "may, will, expect, anticipate,
continue, estimate, project or intend" and similar expressions identify
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E Securities Exchange Act of 1934 regarding events,
conditions and financial trends that may effect our future plan of operation,
business strategy, operating results and financial position. Current
stockholders and prospective investors are cautioned that any forward-looking
statements are not guarantees of future performance and are subject to risks and
uncertainties and that actual results may differ materially from those included
within the forward-looking statements as a result of various factors. Such
factors are described under the headings "Business-Certain Considerations,"
"Management's Discussion and Analysis of Financial Condition and Results of
Operations," and the financial statements and their associated notes.

Important factors that may cause actual results to differ from projections
include, for example:

o    the success or failure of management's efforts to implement their business
     strategy;
o    our ability to protect our intellectual property rights;
o    our ability to compete with major established companies;
o    our ability to attract and retain qualified employees; and
o    other risks which may be described in future filings with the SEC.









                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                                  BALANCE SHEET



                                                       September 30,     December 31,
                                                       2001              2000
                                                       (Unaudited)
                                                       ------------------------------
CURRENT ASSETS

    Cash and Cash Equivalents                          $         406     $    218,770
    Accounts Receivable                                        4,786           21,688
    Due from Officer/Shareholder                              50,000           50,000

    Prepaid Expenses and Other                                28,108           42,237
                                                       -------------     ------------

        Total Current Assets                                  83,300          332,695

    Property and Equipment, at Cost,
        (Net of Accumulated Depreciation
         of $81,144 and $56,438, respectively)               130,924          188,830

    Deposits                                                   1,395            1,395

    Due from Officer/Shareholder, Net of Allowance
      for Doubtful Amounts of $200,000                         -                  -

    Deferred Income Tax Asset, Net of Valuation
      Allowance of $2,184,000 and $1,968,000,
      respectively)                                            -                  -
                                                       -------------     ------------

      Total Assets                                     $     215,619     $    522,920
                                                       =============     ============


                               LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENT LIABILITIES
    Accounts Payable and Accrued Expenses              $     261,551     $    175,350

    Due to Officer/Shareholder                                35,000             -
    Litigation Settlement Payable                          1,000,000        1,000,000
    Deposits on Common Stock to be Issued                     93,470           69,397
    Notes Payable                                            250,000             -

    Other Liabilities                                         20,000             -


        Total Current Liabilities                          1,660,021        1,244,747
                                                       -------------     ------------


STOCKHOLDERS' DEFICIENCY

    Preferred Stock $.001 Par Value, 5,000,000
     Shares Authorized;
        Issued and Outstanding, 30,000 Shares                     30               30
    Common Stock, $.001 Par Value, 300,000,000
     Shares Authorized;
        Issued and Outstanding, 55,623,480 and
         54,815,336 Shares, respectively                      55,623           54,815
    Additional Paid in Capital                             8,807,999        8,427,840
    Deficit Accumulated During the Development Stage    (10,263,380)      (9,159,838)
    Common Stock in Treasury (600,000 Shares at Cost)          (600)            (600)
    Subscriptions Receivable                                (44,074)         (44,074)
                                                       -------------     ------------

        Total Stockholders' Deficiency                   (1,444,402)        (721,827)
                                                       -------------     ------------

        Total Liabilities and Stockholders' Deficiency $     215,619     $    522,920
                                                       =============     ============


The accompanying notes are an integral part of these financial statements.

                                       1





                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                             STATEMENT OF OPERATIONS

                                   (Unaudited)




                                                                                                    For the Period
                                               For the Three Months      For the Nine Months         from Inception
                                                Ended September 30,       Ended September 30,       to September 30,
                                                 2001         2000           2001        2000              2001
                                             -----------  -----------  ------------  -----------  --------------------

REVENUES                                     $  17,242    $    23,361  $     41,976  $    30,611  $            220,719
                                             -----------  -----------  ------------  -----------  --------------------

COSTS AND EXPENSES:
    General and Administrative                   362,849      494,968     1,079,172    1,477,379             5,733,764
    Research and Development                      58,819       33,402       106,642      159,067             1,059,023
    Settlement Costs                                   -            -             -            -             1,870,000
    Financing Costs                                    -            -             -            -             2,095,704
                                             -----------  -----------  ------------  -----------  --------------------

        Total Operating Expenses                 421,668      528,370     1,185,814    1,636,446            10,758,491
                                             -----------  -----------  ------------  -----------  --------------------

Other Income (Expense)
    Interest Income                                   -         5,457         8,261       34,752               104,641
    Interest Expense                            (38,975)            -      (54,795)            -              (55,794)
    Gain on Sales of Resonance Machines               -        10,364        86,830       44,881               225,545
                                             -----------  -----------  ------------  -----------  --------------------

NET LOSS                                     $ (443,401)  $ (489,188)   (1,103,542) $(1,526,202)  $       (10,263,380)
                                             ===========  ===========  ============  ===========  ====================



PER SHARE INFORMATION:

Net Loss Per Share:
    Basic                                    $    (0.01)  $    (0.01)  $     (0.02)  $    (0.03)
                                             ===========  ===========  ============  ===========
    Diluted                                  $    (0.01)  $    (0.01)  $     (0.02)  $    (0.03)
                                             ===========  ===========  ============  ===========

Shares Used to Compute Net Loss Per Share
    Basic                                     55,623,480   54,615,336    55,492,696   46,469,164
                                             ===========  ===========  ============  ===========
   Diluted                                    55,623,480   54,615,336    55,492,696   46,469,164
                                             ===========  ===========  ============  ===========


The accompanying notes are an integral part of these financial statements.

                                       2



                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
               For the Period form Inception to September 30, 2001
                                   (Unaudited)
                                                                                 DEFICIT
                                                                              ACCUMULATED                        STOCK-
                                                                   ADDITIONAL DURING THE               COMMON    HOLDERS'
                                COMMON STOCK     PREFERRED STOCK   PAID-IN    DEVELOPMENT SUBSCRIPTION STOCK IN  EQUITY
                             ----------------------------------------------------------------------------------------------
                               ISSUED   AMOUNT   ISSUED   AMOUNT   CAPITAL    STAGE       RECEIVABLE   TREASURY (DEFICIENCY)
                             ----------------------------------------------------------------------------------------------

 Issuance of Founders
  Stock at Par $.001         57,220,000 $57,220    -         -     $ (57,220) $    -      $    -       $   -   $    -

 Recapitalization
  - June 4, 1996              4,905,000   4,905    -         -        (4,905)      -           -           -        -

 Issuance of Common
  Stock at $.10 Per Share    10,000,000  10,000    -         -        990,000      -         (526,550)     -    473,450

 Issuance of Common Stock
  at $1.75 Per Share             18,857      19    -         -         32,981      -           -           -     33,000

 Purchase of Treasury Stock
  at Cost                         -        -       -         -          -          -           -         (600)     (600)

 Conversion of Common Stock
  to Preferred Stock       (45,000,000)(45,000)   45,000        45     44,955      -           -           -        -


 Net Loss                         -        -       -         -          -        (292,325)     -           -   (292,325)

 Balance, December 31, 1996  27,143,857  27,144   45,000        45  1,005,811    (292,325)   (526,550)    (600) 213,525

 Issuance of Common Stock
  for Services Rendered at
   Prices Between $.15 and
   $1.75 Per Share               40,114      40     -        -         12,744      -           -           -     12,784

 Issuances of Common Stock
  from Private Placement at
   Prices Between $.15 and
   $.25 Per Share               760,000     760     -        -         39,240      -           -           -    140,000

 Issuances of Common Stock
  out of Proceeds of
   Subscription Receivable       -         -        -        -          -          -             5,000     -      5,000

 Net Loss                        -         -        -        -          -        (315,319)     -           -   (315,319)


 Balance, December 31, 1997  27,943,971  27,944   45,000        45  1,157,795    (607,644)   (521,550)    (600)  55,990


Reacquisition of Common
 Shares and                 (3,000,000) (3,000)     -        -      (450,000)      -           450,000     -     (3,000)
  Collection of Subscription
  Receivable


Cash Collection of
 Subscription Receivable        -          -       -         -          -          -            27,476     -     27,476

Issuance of Common Stock
 from Private
   Placement at a Price of
   $.15 per Share             4,675,850   4,676    -         -        659,294      -            -          -    663,970

Issuance of Common Stock
 from Private Placement at
 a Price of $.35 per Share    2,017,999   2,018    -         -        690,156      -            -          -    692,174

Issuance of Common Stock
 for Services

   Rendered at Prices
    between $.15 and $.35
    per Share                   663,223     663    -         -        176,415      -           -           -    177,078


Fair Value of Options Issued
 to Consultants                   -         -      -         -          2,063      -           -           -      2,063

Net Loss                          -         -      -         -           -       (952,276)     -           -   (952,276)


 Balance December 31, 1998   32,301,043  32,301   45,000        45  2,235,723  (1,559,920)    (44,074)    (600) 663,475



The accompanying notes are an integral part of these financial statements.

                                       3



                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
            STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Continued)
               For the Period form Inception to September 30, 2001
                                   (Unaudited)
                                                                              DEFICIT
                                                                              ACCUMULATED                       STOCK-
                                                                   ADDITIONAL DURING THE               COMMON   HOLDERS'
                              COMMON STOCK       PREFERRED STOCK   PAID-IN    DEVELOPMENT SUBSCRIPTION STOCK IN EQUITY
                             -----------------------------------------------------------------------------------------------
                             ISSUED      AMOUNT  ISSUED   AMOUNT   CAPITAL    STAGE       RECEIVABLE   TREASURY (DEFICIENCY)
                             -----------------------------------------------------------------------------------------------


 Balance December 31, 1998   32,301,043   32,301   45,000       45  2,235,723 (1,559,920)     (44,074)    (600) 663,475

Issuance of Common Stock
 for Services
   Rendered at Prices
    between $.18 and $2.69
    per Share                 1,313,903    1,314     -        -       420,375     -              -         -    421,689

Issuance of Common Stock
  for Repayment of Debt         291,305      291     -        -        60,883     -              -         -     61,174

Issuance of Common Stock
 for Exercise of Warrants       900,000      900     -        -     1,754,100     -              -         -  1,755,000

Sales of Shares at $.20
 per Share                      500,000      500     -        -        99,500     -              -         -    100,000

Beneficial Conversion
 Feature on Convertible
 Debentures                       -        -         -        -       333,332     -              -         -    333,332

Issuance of Common Stock
 for Conversion of
 Debentures                   1,862,876    1,863                      902,194     -              -         -    904,057


Net Loss                          -        -         -        -         -     (3,657,966)        -         - (3,657,966)

 Balance, December 31, 1999  37,169,127   37,169   45,000       45  5,806,107 (5,217,886)     (44,074)    (600) 580,761

Issuance of Common Stock
 for Services Rendered at
 Prices between $.21 and
 $1.52 per Share                385,342      385     -        -       378,555     -              -         -    378,940

Sales of Shares a $.13
 to $.65 per Share            2,120,867    2,121     -        -     1,095,497     -              -         -  1,097,618

Fair Value of Options
 Issued to Consultants            -        -         -        -       242,031     -              -         -    242,031

Fair Value of Options
 Issued on Settlement             -        -         -        -       870,000     -              -         -    870,000

Issuance of Common Stock
 for Exercise of Options        140,000      140     -        -        50,635     -              -         -     50,775

Issuance of Common Stock
 Upon Conversion of
  Preferred Stock            15,000,000   15,000 (15,000)     (15)   (14,985)     -              -         -        -


Net Loss                          -        -         -        -         -     (3,941,952)        -         - (3,941,952)
                             --------- --------- -------- -------- ---------- ----------- ------------ -------- ------------

Balance, December 31, 2000   54,815,336   54,815   30,000       30  8,427,840 (9,159,838)     (44,074)    (600)(721,827)

Issuance of Common Stock
 for Services
  Rendered at Prices
  between $.30 and $.35
  per Share                     210,112      210     -        -        70,938    -               -         -     71,148

 Issuances of Common Stock
 from Private Placements at
     Prices Between $.25
     and $.42 Per Share         598,032      598     -        -       166,450    -               -         -    167,048

Fair Value of Options Issued
 to Consultants                   -        -         -        -       142,771    -               -         -    142,771


Net Loss                          -        -         -        -         -     (1,103,542)        -         - (1,103,542)
                             --------- --------- -------- -------- ---------- ----------- ------------ -------- ------------
                                                                                                            $(1,444,402)
Balance, September 30, 2001  55,623,480 $ 55,623  30,000 $     30 $8,807,999 $(10,263,380)$   (44,074) $ (600)
                             ========= ========= ======== ======== ========== =========== ============ ====== ==========

The accompanying notes are an integral part of these financial statements.

                                       4





                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                             STATEMENT OF CASH FLOWS
                                   (Unaudited)
                                                                                                       For the Period
                                                                                                       from Inception
                                                         For the Nine Months Ended September 30,       to September 30,
                                                                 2001            2000                        2001
                                                           ------------------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
    Net Loss                                               $  (1,103,542)    $ (1,526,202)             $   (10,263,380)
    Adjustments to Reconcile Net Loss to Net Cash
       Used in Operating Activities:
            Depreciation                                           29,985           27,622                       86,423
            Amortization                                          -                -                              7,742
            Allowance for Doubtful Amounts Due from
             Officer/Shareholder                                  -                -                            200,000
            Write off of Licensing Costs                          -                -                            126,582
            Fair Value of Common Stock Issued for Services
             Rendered                                              71,148          368,000                    1,061,857
            Fair Value of Common Stock Issued for Interest
             Expense                                              -                -                              6,781
            Stock Issued for Conversion of Warrants
             Attributed to Interest                               -                -                          1,754,100
            Beneficial Conversion Feature of Debentures           -                -                            333,332
            Fair Value of Options Issued                          142,771          198,801                    1,256,865
            Disposition of Property and Equipment                  31,238          -                             31,238

        Changes is Operating Assets and Liabilities:
            Accounts Receivable                                    16,902         (13,300)                      (4,786)
            Prepaid Expenses and Other                             14,129           14,249                     (28,108)
            Deposits                                              -                (3,245)                      (1,395)
            Accounts Payable and Accrued Expenses                  86,202         (40,431)                      261,552
            Other Liabilities                                      20,000          -                             20,000
            Litigation Settlement Payable                         -                -                          1,000,000
                                                           --------------    -------------             ----------------

Net Cash Used in Operating Activities                           (691,167)        (974,506)                  (4,151,197)
                                                           --------------    -------------             ----------------
CASH FLOWS FROM INVESTING ACTIVITIES:
    Purchase of Property and Equipment                            (3,318)         (77,387)                    (248,586)
    Loans made to Shareholder and Employee                        -              (250,000)                    (250,000)
    Patent Costs                                                  -                -                          (126,582)
                                                           --------------    -------------             ----------------

Cash Used in Investing Activities                                 (3,318)        (327,387)                    (625,168)
                                                           --------------    -------------             ----------------
CASH FLOWS FROM FINANCING ACTIVITIES:

    Purchase of Treasury Stock                                    -                -                              (600)
    Proceeds from Notes Payable                                   250,000                                       310,000
    Proceeds from Officer/Shareholder                              35,000          -                             35,000
    Proceeds from Issuance of Debentures                          -                -                            890,490
    Proceeds from Exercise of Warrants                            -                -                                900
    Proceeds from Exercise of Options                             -                 50,775                       50,775
    Proceeds from Common Stock to be Issued                        93,470          -                            162,867
    Proceeds from Issuance of Common Stock
        from Subscriptions Receivable                             -                -                            653,976
    Proceeds from Issuance of Common Stock                         97,651        1,077,618                    2,673,363
                                                           --------------    -------------             ----------------

Net Cash Provided by Financing Activities                         476,121        1,128,393                    4,776,771
                                                           --------------    -------------             ----------------

Net Increase (Decrease) in Cash and Cash Equivalents            (218,364)        (173,500)                          406

Cash and Cash Equivalents - Beginning of Period                   218,770          579,518                      -
                                                           --------------    -------------             ----------------

Cash and Cash Equivalents - End of Period                  $          406    $     406,018             $            406
                                                           ==============    =============             ================

NONCASH INVESTING AND FINANCING ACTIVITIES:


  Issuance of Common Stock for Repayment of Debt           $      -          $      -                  $         60,000
                                                           ==============    =============             ================

  Issuance of Common Stock for Deposits                    $       69,397    $      -                  $         69,397
                                                           ==============    =============             ================

  Subscriptions Receivable for Issuance of Common Stock    $      -          $     -                   $        698,050
                                                           ==============    =============             ================

  Conversion of debentures into common stock               $      -          $     -                   $      1,000,000
                                                           ==============    =============             ================

The accompanying notes are an integral part of these financial statements.

                                       5





                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                          NOTES TO FINANCIAL STATEMENTS
                  For the Nine Months Ended September 30, 2001
                                   (Unaudited)

NOTE 1 - BASIS OF PRESENTATION

The accompanying financial statements for the interim period are unaudited and
reflect all adjustments (consisting only of normal recurring adjustments) which
are, in the opinion of management necessary for a fair presentation of the
financial position and operating results for the periods presented. These
financial statements should be read in conjunction with the financial statements
and notes thereto, together with Management's Discussion and Analysis of
Financial Condition and Results of Operations, contained in the Annual Report on
Form 10-KSB for the year ended December 31, 2000, of Jacobson Resonance
Enterprises, Inc. (the "Company") as filed with the Securities and Exchange
Commission. The results of operations for the three and nine months ended
September 30, 2001 are not necessarily indicative of the results for the full
fiscal year ending December 31, 2001.

NOTE 2 - DUE TO OFFICER/SHAREHOLDER

In the third quarter of 2001, an officer/shareholder pledged 3,800,000 of his
shares to personally borrow up to $61,250 to provide financing for the Company.
The officer/shareholder loaned $35,000 to the Company as of September 30, 2001
with the remaining $23,250 loaned subsequently.

NOTE 3 - NOTES PAYABLE

In the second and third quarters of 2001, the Company received $250,000 from the
proceeds of several promissory notes. Each of these notes were for a term of 60
days and bears interest at a rate of 5% per annum. At September 30, 2001, the
Company was in default on all $250,000 of these notes.

Under the terms of the notes, in the event of default, the note holder has the
option to purchase 10,000 shares of the Companys common stock for $100 for
each $25,000 of outstanding debt. Additionally, the notes state that the note
holders can continue to purchase common stock in the Company at a rate of 5,000
shares of common stock for $50 for each $25,000 of outstanding debt for each 30
day period until the notes are paid in full. At September 30, 2001, the Company
had received $1,050 for 105,000 shares. The $1,050 is included in the
accompanying balance sheet as deposits on common stock to be issued as the
shares have not yet been issued. In October 2001, the Company issued 110,000
shares to satisfy the defaults.

The Company is recording interest expense for the difference between the fair
market value of the Companys common stock on the date the loan proceeds
are received and the exercise price of $.01 per common share for any shares that
the note holders have a right to receive. The interest charge for the nine
months ended September 30, 2001 was approximately $50,000.


                                       6



                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                          NOTES TO FINANCIAL STATEMENTS
                  For the Nine Months Ended September 30, 2001
                                   (Unaudited)


NOTE 4 - STOCKHOLDERS' EQUITY

In January 2001, the Company issued 210,112 shares of common stock at prices
between $.30 and $.35 for services which included 165,000 shares under a
continuing agreement for product endorsements. An aggregate of $71,148 was
charged to operations during the nine months ended September 30, 2001.

In March 2001, the Company issued common stock pursuant to two private
placements. In the first private placement, the Company issued 198,032 shares of
common stock at a price of $.42 per share (Including 165,232 shares for $69,397
received in 2000). The Company still owes 1,000 shares related to this private
placement. Under the terms of this private placement, investors received one
Class A warrant which are exercisable at $.63 per common share for a four-year
period extending through December 31, 2004 and potentially one Class B warrant
which will be issued when and if the Class A warrants are exercised on or before
December 31, 2001 which are exercisable at $.84 per common share for a five-year
period extending through December 31, 2005 for each share of common stock
purchased.

In September 2001, the Company entered into agreements to sell 772,729 shares of
common stock at prices between $.11 and $.15 per share. The shares were not
issued until October 2001. The proceeds of $92,000 are included in the balance
sheet as deposits on common stock to be issued. In October 2001, the Company
sold an additional 303,030 shares of common stock at $.11 per share.

In March 2001, the Company issued 335,500 shares of common stock at $.25 per
share under the terms of the second private placement which has been closed. In
addition, 64,500 shares of common stock were issued to the individual who helped
arrange the private placement.

In April 2001, the Company approved the granting of options to purchase
4,392,500 shares of common stock at a price of $.30 per share. Options to
purchase 4,310,000 shares of common stock were issued to employees and
directors. Options to purchase 82,500 shares of common stock were issued to
non-employees for services and were valued using the Black-Scholes option
pricing model at $23,793 and were charged to operations during the quarter
ended June 30, 2001.

In July 2001, the Company approved the granting of options to purchase
11,045,000 shares of common stock at a price of $.25 per share. Options to
purchase 10,875,000 shares of common stock were issued to employees and
directors. Options to purchase 170,000 shares of common stock were issued to
non-employees for services and were valued using the Black-Scholes option
pricing model at $30,753 and were charged to operations during the quarter
ended September 30, 2001.

In September 2001, the Company entered into a consulting agreement for marketing
services for a term of six months. Under the terms of this agreement, the
Company issued the consultant options to purchase 350,000 shares of the
Companys common stock at a price of $.19 per share. These options are
exercisable for a period of twenty-four months. These options have been valued
using the Black-Scholes option pricing model which has resulted in a charge to
operations of $32,410.

In October 2001, the Company issued 560,000 shares of common stock for financial
consulting and marketing services. One of these agreements began prior to the
end of the third quarter and this has resulted in a prepaid expense and an
accrual of $6,481 in the accompanying balance sheet. Under the terms of the
consulting agreements, the Company also issued 100,000 options at $.25, 100,000
options at $.35, 75,000 options at $.50 per share which are exercisable for a
period of three years. These options have been valued using the Black-Scholes
option pricing model which has resulted in a charge to operations of $55,815.


                                       7



ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
             CONDITION AND RESULTS OF OPERATIONS

     Certain statements contained in this report, including, without limitation,
statements containing the words "believes," "anticipates," "expects" and words
of similar import constitute "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks and uncertainties. The Company's
actual results may differ materially from those anticipated in these
forward-looking statements as a result of certain factors, including the success
and subsequent acceptance of new medical research and development; the
regulatory framework of the health care industry; the Company's ability to
create, sustain, manage or forecast its growth; its ability to attract and
retain key personnel; its ability to protect technology; changes in its business
strategy or development plans; competition; demographic changes; business
disruptions; adverse publicity; and international, national and local general
economic and market conditions.

PLAN OF OPERATION

     The Company is in the development stage and has received some royalty
revenues from Real Pure Beverage Group, LLC, Bio Resonance Technology, Inc.,
Canada and Palmer Natural Products, Inc., San Juan Capistrano, California during
the third quarter of 2001. The Company has incurred losses of approximately
$1,100,000 for the nine months ended September 30, 2001. It has incurred losses
of approximately $10,200,000 since its inception. Of that amount, approximately
$4,400,000 represents the non-cash expense resulting from the issuance of common
stock and options to purchase common stock to members of the Company's
management and third parties for services rendered and interest.

2001 Operations Compared to 2000

     The net loss decreased from approximately $1,500,000 to approximately
$1,100,000 for the nine months ended September 30, 2000 as compared to September
30, 2001. This change is primarily as a result of a decrease in noncash
compensation for the nine months ended September 30, 2001 of approximately
$400,000 and management cost controls. In addition, the net loss decreased from
approximately $500,000 to approximately $400,000 for the three month period
ended September 30, 2000 to 2001 resulting from a reduction in noncash
compensation.

     Since early May 2000, the Company jointly launched its marketing campaign
with Real Pure Beverage Group, LLC, for promoting resonated high energy sport
drink (Real Pro). Brett Favre is the official spokesperson for Real Pro sports
drink produced and bottled by Real Pure Beverage Group, LLC. These marketing and
national distribution initiatives continue and have expanded during 2001.

     In addition, the Company has received approval and a CE-Mark issuance from
the European Union, thus allowing distribution and commercialization of its
medical resonators in 2001. Marketing and distribution plans through EKINSA are
currently ahead of schedule. The Company has also received approval by Health
Canada licensing authorities for commercialization and distribution of medical
resonators and said license has now expanded not only to cover all medical
resonator models but also licensing clearance by Health Canada covering "all
types of pain" instead of being limited to arthritic pain. Bio Resonance
Technology, Inc., now operates two medical centers (Calgary and Winnipeg) and a
third center under planning and construction for southeast Canada.

     Serrator Europe, SARL, Geneva, Switzerland, is currently under a global
expansion through its' worldwide sub-license EKINSA of Madrid, Spain. Plans are
currently underway to expand distribution, marketing and sales into Germany,
Portugal and France as well as key countries in Latin America such as Mexico,
Venezuela and Argentina during 2001 and 2002 thus generating a royalty stream
for JRSE. (See September 2001 - PR Newswire Press Release.) Additional health
clearances and approvals have been granted in Australia, Finland and Norway.
Currently, Serrato Europe, SARL, is developing additional distribution and
marketing plans to cover these and other countries expected to receive
clearances over the next six months.

     The Company expects FDA clearance of its 18" clinical resonator sometime
before the end of 2001. The Company currently has on file a 510-k submission to
the Radiological Division of FDA which is under review. In December 2001, the
Company is expected to meet with FDA management personnel and authorities in
order to discuss the Company's submission and other pending matters dealing with
the clearance, development, future research studies, and submissions of the
Jacobson Resonator and resonance technology advancements. The Company further
expects to receive a broad "pain spectrum" clearance sometime in late 2002 or
early 2003 as further research and clinical trials are completed and presented
to FDA for additional clearances.

     The Company's agricultural, environmental and building licensing
initiatives continue to show tremendous potential and interest particularly in
the Pan Asian and Pacific Rim countries. As a result, the Company continues to
investigate licensing and joint venture opportunities in the region, from which
it expects to generate additional revenues. Research at Texas A&M University,
Mississippi State University and the University of Oklahoma have shown positive
results that Jacobson Resonance Technology can beneficially affect the growth
cycle of vegetables, fruits and liquids. The foregoing combination of events is
also expected to generate ongoing revenues even though it is not a primary focus
of the Company. These revenues from non-medical initiatives are expected to grow
during the fourth quarter of 2001 and beyond.

Other possible sources of revenue for the Company during fiscal 2001 include the
following:

1.   Licensing revenue from a larger medical products company for the
     development, marketing and distribution rights in connection with the use
     of Jacobson Resonance in the treatment of cardiac arrhythmia. Results thus
     far in cardiac pacing research at the University of Oklahoma Health Science
     Center have attracted interest by several major international medical
     device corporations.

2.   Licensing revenue from Palm7er Natural Products, Inc. and Perfect Living
     Systems, Inc., two nutraceutical laboratories and formulary companies
     located in southern California. The Company has received initial royalty
     revenues from both of these firms in September 2001 covering third quarter
     payments. This royalty stream is expected to increase and continue during
     the fourth quarter of 2001 and beyond.

3.   Licensing revenue from existing licensee for building, construction and
     the environment from Enviro Brick and Block Ltd. and Enviro Products, Ltd.
     The Company has signed an exclusive licensing agreement since August 2000.
     Royalty revenues from new and existing Canadian and U.S. manufacturing
     plants are expected to commence by late second quarter or early third
     quarter of 2002.

4.   Additional revenues from pending non-medical resonance licensing
     agreements which are currently under negotiations, legal review, and board
     approval which have not been made public as of the end of third quarter,
     but could substantially contribute in royalty revenues to the Company
     during 2002 and 2003.

5.   Expansion of global marketing and distribution services by EKINSA,
     Serrato Europe and Serrator Medical in Latin America, Middle East and
     Pacific Rim countries in addition to the European Union.

     The Company will continue both use and product research and development for
Jacobson Resonance as a key ingredient in having numerous proven applications
and uses of its resonance technology to provide revenue stream in medical as
well as targeted non-medical areas through 2002 and 2003. It anticipates
continued prototyping of additional models of the Jacobson Resonator for varying
uses as funding becomes available for that purpose. The Company estimates
approximately $40,000 in prototyping in 2001 and approximately $110,000
additionally in 2002 for a combined total of $150,000 in prototyping design.

LIQUIDITY AND CAPITAL RESOURCES AS OF SEPTEMBER 30, 2001

     The Company's cash on hand at September 30, 2001, was $406, as compared to
$406,018 at September 30, 2000. Revenues for the quarter ended September 30,
2001 were $17,242 as compared to $23,361 for the quarter ended September 30,
2000. The Company had a net loss of approximately $1,100,000 for the nine months
ended September 30, 2001 as compared to a net loss of approximately $1,500,000
for the nine months ended September 30, 2000.

     Since the beginning of the year, the Company has received approximately
$93,000, from the sale of securities and $285,000 from the proceeds of several
notes payable. The Company anticipates that its existing resources will be
sufficient to fund its plan of operation through 2001 and beyond. By the end of
2001, the Company expects to be generating sufficient revenue to fund its plan
of operation. However, if the Company by that time is not generating any revenue
or is generating insufficient revenue for such funding, then the Company may
have to seek additional funds through either debt or equity financing. The
Company's year-end financial statements include an explanatory paragraph about
the Company's ability to continue as a going concern.

     The Company entered into a retainer agreement with the law firm of Jackson
Campbell, P.A., Washington, D.C. as a financial consultant and corporate
representative for special projects. The Company has also entered into a
retainer agreement with the law firm of Norman Sirak, Esq. of Canton, Ohio and
Washington, DC, as well as the law firm of Richard P. Greene, P.A. of Ft.
Lauderdale, Florida for SEC compliance.

     In April 2001, the Company entered into a consulting agreement with
Regulatory Insight, Inc., of Lakewood, Colorado for healthcare consulting
services in addition to having a service healthcare consulting agreement for FDA
since September 2000 with Quintiles Inc. and the Lewin Group.

     The Company has also entered into three agreements during third quarter
2001 with a communications company (EquityLink), public relations consultant
(CFC Enterprises, Inc.) and market consulting financial firm (1st.Source
Communications) for the purpose of enhancing education and knowledge about the
Company's technology, applications, and opportunities to the investment
community at large.

     Note 3 of the financial statements refers to the fact that the Company
received $250,000 from the proceeds of several promissory notes which have 60
days terms and pay interest at 5% per annum. Note 3 reflects that the Company is
in default. Management and the parties mutually understood that the 60 days term
would not be met prior to execution of the notes. Although management agrees
that the payment is late, management maintains the default is only technical
since the contemplated late penalty provision entitles the Company to a roll
over extension provision and entitles the holders options to purchase shares of
the Company's common stock. Both parties have agreed upon entering this note
that the roll over provision would be used.


                                       8




                           PART II - OTHER INFORMATION

ITEM 1.   LEGAL PROCEEDINGS

     The Company is not involved in any legal proceedings or litigation, and the
officers and directors are aware of no other pending litigation. The Company and
Dr. Jerry Jacobson are, however, seeking sources of equity financing for the
purpose of satisfying the terms and conditions of a settlement agreement with
Eric Hewko and Patrick Casey entered into on March 2, 2001. Dr. Jacobson filed
for bankruptcy and on December 6, 2000, the case was dismissed.

ITEM 2.   CHANGES IN SECURITIES

     None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
     None



ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     None.

ITEM 5.  OTHER EVENTS

     None.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8_K

     There were no reports on Form 8-K filed by the registrant for the quarter
ending September 30, 2001



                                       9





                                   SIGNATURES

     Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.


                                            JACOBSON RESONANCE ENTERPRISES, INC.

Date: April 25, 2002               By:  /s/ Jerry I. Jacobson
----------------------
                                       Jerry I. Jacobson, Chairman of the Board
                                       and Chief Executive Officer

     Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the date indicated.

Date: April 25, 2002               By:  /s/ Jerry I. Jacobson
----------------------
                                       Jerry I. Jacobson, Chairman of the Board
                                       and Chief Executive Officer
                                       (Principal Executive Officer)

Date: April 25, 2002               By:  /s/ Debra M. Jacobson
----------------------
                                       Debra M. Jacobson, Director, Senior Vice
                                       President, Treasurer and Secretary
                                       (Principal Financial and Accounting
                                        Officer)


                                       10`